Fampridine: Evaluation of effectiveness of Fampridine and comparison with the clinical trail


Department of Clinical Pharmacy- Instituto de Investigación Biosanitaria de Granada Hospital Universitario San Cecilio- Granada- Spain., Pharmacy, Granada, Spain

BACKGROUND
Fampridine has been approved for the improvement of walking capacity (WC) in multiple sclerosis adult patients with Expanded Disability Status Scale (EDSS) 4-7.

OBJECTIVES:
To evaluate the effectiveness of fampridine in WC of MS patients.

MATERIAL AND METHODS
Data were obtained from reviewing patient's clinical records from Neurology department. Patients with MS and disability score (EDSS) between 4-7 and treated with fampridine 10 mg/12h from October 2014 to May 2015 were evaluated in a retrospective study. Parameters measured: At baseline and 15 days after the first dose.

- Timed 25-foot walk test (T25FW)
- 12-item MS walking scale (MSWS-12) questionnaire.

* Responder patients were those with T25FW decrease ≥20% from baseline.

RESULTS

<table>
<thead>
<tr>
<th>N=45</th>
<th>Age (mean, SD)</th>
<th>49.93 (±9.98)</th>
<th>Women %</th>
<th>68.9</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MS type</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Relapsing remitting</td>
<td>64.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Primary progressive</td>
<td>13.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Secondary Progressive</td>
<td>22.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>EDSS (mean, SD)</td>
<td>5.55 (±0.92)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T25FW (mean, SD)</td>
<td>20.56 (±11.49)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MSWS (mean, SD)</td>
<td>53.23 (±4.5)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

At 15th day:

- TW25F was 13.29 (average reduction 34%)
- 71.1% presented at least 20% reduction of the TW25F.
- MSWS-12 was 34.94 (average 15.73 points).
- Although 13 patients (28.9%) did not improve TW25F
- 10 patients discontinued the treatment, 2 because intolerance.

In the pivotal clinical trial there was a global average T25FW reduction of 35%. We evaluated the association between response (T25FW) and EDSS (> or < 6.5 at baseline) and there were no significant differences.

CONCLUSION
Fampridine produces a clinical hold-in-time improvement in walking capacity in our population similarly those showed on the clinical trail.